Is there a Distinct Phenotype to Memory Loss in Alzheimer's Disease?



Similar documents
Primary Endpoints in Alzheimer s Dementia

CRITERIA FOR AD DEMENTIA June 11, 2010

Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Biomarkers for Alzheimer's Disease in Down Syndrome

MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

Clinical Features of Mild Cognitive Impairment and Dementia in a Community: An update of the Osaki-Tajiri Project

Diseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University

Current Industry Neuroimaging Experience in Clinical Trials Jerome Barakos, M.D.

Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI)

Human recognition memory: a cognitive neuroscience perspective

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

Cognitive Interventions for Mild Cognitive Impairment

Alzheimer s disease. What is Alzheimer s disease?

Alzheimer s & Dementia 7 (2011)

WMS III to WMS IV: Rationale for Change

GOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY BE AN EFFECTIVE TREATMENT FOR ALZHEIMER S DISEASE AND VASCULAR DEMENTIA

Normal and Abnormal Aging and the Brain. Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

Bedside cognitive examination beyond the MMSE. Dr Richard Perry Dept of Neurosciences Imperial College

ANXIETY & COGNITIVE IMPAIRMENT

Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease

Automatic Morphological Analysis of the Medial Temporal Lobe

Clinical Research Infrastructure

Prediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment

Gene E. Alexander, Ph.D. Elsa Baena

Dementia: Delivering the Diagnosis

Brain Structures That are Involved with Memory

Predicting the future progression of dementia. Ashish Raj, PhD

AQT-D. A Quick Test of Cognitive Speed. AQT-D is designed for dementia screening.

Sandro Sorbi DIPARTIMENTO DI SCIENZE NEUROLOGICHE E PSICHIATRICHE

Copywrite - Eric Freitag, Psy.D., 2012

The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia

Collaborative Care for Alzheimer s Disease

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

2016 Programs & Information

COGNITION IN AGING AND AGE-RELATED DISEASE

Neuropsychology Research Program: Thomas P. Ross, Ph.D.

Alzheimer s & Dementia 9 (2013) e1 e16

2 Neurons. 4 The Brain: Cortex

CONTE Summer Lab Experience Application

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Guidance for Industry Alzheimer s Disease: Developing Drugs for the Treatment of Early Stage Disease

DOTT. GIOVANNI CARLESIMO ELENCO DELLE PUBBLICAZIONI ANNI

Attention, memory and learning and acquired brain injury. Vicki Anderson. Jamie M. Attention & learning: an information processing model

Diagnosis and Initial Management of Cognitive Disorders

Frequently Asked Questions

Applied Nursing Research

Simposio Internacional: International Symposium Murray Grossman

THEORIES OF NEUROLOGICAL AGING AND DEMENTIA

How To Navigate Early-Stage Alzheimer s Disease

FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov

Attention & Memory Deficits in TBI Patients. An Overview

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

1 st December Cardiff Crown Court. Dear. Claimant: Maurice Kirk Date of Birth: 12 th March 1945

Appropriate Use of CPT Coding in Treatment of Persons with Memory Impairment

Pradeep Redddy Raamana

Scandinavian Bio-Business Seminar, Zürich. Presentation 10 February 2016 Håkon Sæterøy, CEO

Alzheimer s and Depression: What is the Connection?

WISC IV and Children s Memory Scale

Overview. Neuropsychological Assessment in Stroke. Why a Neuropsychologist. How to make a referral. Referral Questions 11/6/2013

No Dementia Stage 2: Very Mild Cognitive Decline

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault

Local Clinical Trials

Disclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose

Dementia Causes and Neuropsychological Evaluation of the Older Adult

Early Changes in the Brain Proteome Associated with Alzheimer's Disease Risk

Auditory memory and cerebral reorganization in post-linguistically deaf adults

Cognitive Neuroscience. Questions. Multiple Methods. Electrophysiology. Multiple Methods. Approaches to Thinking about the Mind

Encyclopedia of School Psychology Neuropsychological Assessment

advancing magnetic resonance imaging and medical data analysis

Staging and Treatment of Dementia

In conjunction with clinical history, structural

Transcription:

Is there a Distinct Phenotype to Memory Loss in Alzheimer's Disease? David A. Wolk, M.D. Assistant Director Penn Memory Center Assistant Professor of Neurology University of Pennsylvania

5 Million

Clinical and Pathological Course of AD Clinical State Normal Pre-Clinical AD Cognitive No No Symptoms State Symptoms? Pathologic State No Disease Plaques Early Changes MCI Mild Symptoms y p Mild-ModMod Changes AD Mild-Severe Symptoms y p Mod-Severe Changes Tangles

Aging Versus AD

Age Associated Cognitive Impairment Park and Reuter Lorenz, Ann Rev. Psychol., 2009

Aging Versus Preclinical/Prodromal AD Quantitative differences E.g. Face name memory test Specificity dependent of degree of age related and AD related change Qualitative differences?

Topographic p Selectivity of AD Mesulam, 1990

Braak & Braak. Acta Neuropath, 1991

Doctor Who

Downton Abbey Sir Richard Carlisle (Ian Glenn)

Dual Process Models of Recognition Memory Two distinct memory processes Familiarity (item memory) Acontextual sense of prior encounter Quantitative Relatively automatic process Recollection (associative, relational) Detailed retrieval, including spatial and temporal context mental time travel Qualitative Controlled Process

Proposed Spatial and Temporal Dissociation of Recollection and Familiarity it Neuroanatomy Recollection: Hippocampus, Frontal control networks Familiarity: Perirhinal cortex/lateral entorhinal area Timing Recollection: Slower Familiarity: Faster

Binding of Items and Context Model Eichenbaum et al., Ann Rev Neurosci, 2007

What Drives Memory Loss with Normal Aging? Buckner, Neuron, 2004 Small et al., Nature Neuroscience, 2012

Is Familiarity Selectively Impaired in MCI (prodromal lad)? Normal aging: g recollection impaired, familiarity intact MCI: Predict familiarity (and recollection) should be impaired Alternative: If familiarity and recollection on strength continuum, expect relative sparing of familiarity

16 MCI; 21 Controls Three process estimation paradigms Wolk et al., Neuropsychologia, 2008

Process-Dissociation Paradigms Intact OLD Rearranged NEW Novel NEW pr = p( Old Intact) p( Old Rearranged) pf = p( Old Rearranged)/(1 pr)

Wolk et al., Neuropsychologia, 2008

Recollection and Familiarity Impaired in MCI (NC: n=81; MCI: n=65) Recollection Familiarity p<0.001 001 p<0.001001 Control-Referenced z-scores p<0.001 Wolk et al., Neuropsychologia, 2013

Is Familiarity Spared in Normal Aging? (YC: n=18; OC: n=81) Recollection p < 0.0001 Familiarity Wolk et al., Neuropsychologia, 2013

Petersen Criteria for MCI (now referred dto as amnestic MCI) Memory complaint (preferably corroborated by informant) Episodic Memory impairment for age and education Largely intact general cognitive function Essentially preserved activities of daily living Do not meet criteria for dementia

Amnestic MCI Enriched in patients with AD pathology Specialty Clinics 10 to 15% Conversion to clinical AD per year 1 3% in cognitively normal adults 50 80% over 5 years Community Studies (PAQUID, MoVIES) Lower conversion rate (4 to 8%/year) Reversion to normal (10 to 40% over 2 years)

Amyloid Imaging 55-65% PiB positive in most studies of MCI Wolk and Klunk, 2009

Does Familiarity Discriminates MCI Based on Amyloid Status (n=22)? Recollection Familiarity p<0.05

Limited Neuropsychological py Data Familiarity Recollection Rugg and Yonelinas, TICS, 2002 Bowles et al., PNAS, 2007 Guedj et al., Neuropsychologia, 2010

Relationship to MTL Volumes Examined relationship of recollection and familiarity estimates with structure Hippocampus Extrahippocampal MTL (PRC, ERC, PHG) Automated Labeling Pathway (Wu et al., 2006; Andreescu et al., 2007) Wolk et al., Hippocampus, 2011

* * Wolk et al., Hippocampus, 2011

Correlates of Memory in AD Patients from ADNI ADNI participants with clinical AD diagnosis Mean MMSE: 23.3 ±2.0 (SD) MRI of sufficient quality (n=146) MRI analysis Disease specific ROI s (hippocampus, PRC/ERC) Correlate with standard memory measures differentially dependent on recollection/familiarity

Memory Measure Rey Auditory Verbal Learning Test (AVLT) 15 words 5 Immediate memory (learning) trials List B immediate memory 5 minute delayed recall 30 minute delayed recall Recognition memory test

AD Cohort from ADNI (n=146) AVLT Delayed Memory Measures Recollection Recall ** ** Familiarity Recollection Recognition * Wolk & Dickerson, NeuroImage, 2011

Pure Familiarity Recognition discrimination controlled for free recall Wolk and Dickerson, NeuroImage, 2011

Interim Summary Familiarity-based memory is spared as part of normal age-associated cognitive decline Familiarity is dependent on integrity of perirhinal cortex (ERC?) Consistent with early involvement of PRC in AD pathologic process, familiarity-based memory appears sensitive and specific to prodromal AD Is familiarity-based memory sensitive to preclinical AD?

Preclinical Alzheimer s Disease 25-30% of CN adults with AD molecular biomarker profile Consistent t with autopsy data Morris et al., Annals of Neurology, 2010

Cortical Signature of AD Dickerson et al., Cerebral Cortex, 2011

Abnormal Amyloid (PiB) Function Psychometrics Biomar rker Magnit tude Normal Normal Presymptomatic MCI Dementia Clinical disease stage Modified from Jack et al., 2010

Abnormal Amyloid (PiB) Function Biomar rker Magnit tude Psychometrics Brain Structure (MRI) Normal Normal Presymptomatic MCI Dementia Clinical disease stage Modified from Jack et al., 2010

Abnormal Amyloid (PiB) Function Biomar rker Magnit tude Psychometrics Brain Structure (MRI) Brain Physiology (PET) Normal Normal Presymptomatic MCI Dementia Clinical disease stage Modified from Jack et al., 2010

Does Evidence of AD Specific Atrophy Predict tdecline in CN Adults ADNI healthy controls with adequate 1.5 T MRI (n=159) Mean AD signature measure converted to z score > 1 SD bl below mean ADsig hi thin (high h risk ik group) Within 1 SD of mean ADsig Average > 1 SD above mean ADsig thick (lowest risk group) 3 year follow up a priori cutoffs of functional (> 1.0 increase in CDR Sum of Boxes) and cognitive decline (> 1 SD decline)

Cortical Thinning in Signature of AD regions predicts decline and CSF AD profile in Cognitively Normal Adults Dickerson and Wolk, Neurology, 2012

Relationship of AD Cortical Signature with Recollection/Familiarity β=.55, p< 0.001 β=.37, p< 0.05 Wolk et al., Neuropsychologia, 2013

Summary Biomarkers of neurodegeneration may be valuable in temporal prediction in preclinical phases beyond amyloid status Preclinical disease may be associated with subtle cognitive change Familiarity as possible screening measure? Familiarity as cognitive outcome measure in preclinical trials

Collaborators Penn Paul Yushkevich Sandy Das MGH/Harvard Pitt Brad Dickerson John Detre Steve Arnold Steve DeKosky Lauren Mancuso Howard Aizenstein Dasha Kliot Eric Signoff Kti Katie Manning Kathryn Dunfee Funding: K23AG028018; R01AG040271; P30AG010124; Alzheimer s Association